SMN Copy Number Distribution in Mali, West Africa
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01059240|
Recruitment Status : Completed
First Posted : January 29, 2010
Last Update Posted : October 15, 2019
- Spinal muscular atrophy (SMA) is a degenerative and incurable neuromuscular disorder that is caused by mutations in the survival motor neuron gene, SMN1, found on chromosome 5. It is the leading inherited cause of infant mortality. SMA carriers (those who have the genetic mutation but do not have the disease) are often unaware of their status until they are tested.
- Researchers have been studying the prevalence of SMA carriers in the general population, but most of the information collected has come from populations within the United States, Europe, and Asia. Very few studies have been performed in Africa. Furthermore, this information does not provide much information regarding carrier frequency based on ethnic background and ancestry. To address this problem, researchers are interested in studying the prevalence of the SMA genetic mutation in the sub-Saharan nation of Mali.
- To collect blood samples for use in studying genetic data related to spinal muscular atrophy.
- Healthy volunteers who are at least 18 years of age.
- Volunteers will be of Malian ancestry and nationality.
-<TAB>Bamako, Mali, West Africa
- The study will first collect blood samples from a small group of volunteers to run initial SMA carrier testing and resolve any technical difficulties before continuing with the study.
- Participants will complete questionnaires about their personal and family medical history, including questions about illnesses, stillborns, and miscarriages, and then will provide blood samples for genetic research and testing.
|Condition or disease|
|Spinal Muscular Atrophy|
Spinal muscular atrophy (SMA) is an autosomal recessive motor neuron disease that is caused by mutations in the survival motor neuron gene, SMN1. The objective of this study is to determine the SMN copy number distribution in the Malian population and to compare this to published data obtained elsewhere. It is anticipated that this study will help to refine the knowledge of SMA by assessing the distribution of SMN copy number, and the SMA carrier frequency in a sub-Saharan nation, thus expanding the information base available to clinicians and patients considering SMA carrier testing.
The study population will include 1400 adult (18 years of age and older) volunteers only.
Blood samples from volunteers will be collected from students at the School of Medicine, Pharmacy, and Dentistry (FMPOS) at the University of Bamako, which consists of an ethnically diverse population representative of the Malian ethnicities. No therapy will be provided to study participants.
Outcome measure for phase 1 is DNA extraction yield of sufficient quantity and quality for SMN genotyping by LabCorp in at least 90% of samples. Outcome measures for phase 2 are the frequency of SMA carriers (SMN1 deletion heterozygotes) and the SMN1 and SMN2 copy number distribution in Mali.
Abbreviations and Definition of Terms
- SMA: Spinal Muscular Atrophy
- SMN: Survival Motor Neuron
- SMN1: Survival Motor Neuron Telomeric
- SMN2: Survival Motor Neuron Centromeric
|Study Type :||Observational|
|Actual Enrollment :||701 participants|
|Official Title:||SMN Copy Number Distribution in Mali, West Africa|
|Study Start Date :||January 21, 2010|
|Study Completion Date :||May 18, 2017|
- Primary outcome measure for phase 1 is DNA extraction yield of sufficient quantity and quality for SMN genotyping in at least 90% of samples
- Secondary outcome measures for phase 2 are the frequency of SMA carriers (SMN1 deletion heterozygotes) and the SMN1 and SMN2 copy number distribution in Mali.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01059240
|University of Bamako, Faculty of Medicine, Pharmacy and Dentistry (FMPOS)|
|Principal Investigator:||Kenneth H Fischbeck, M.D.||National Institute of Neurological Disorders and Stroke (NINDS)|